drugset
drugset / Trial / NCT04924179

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

NCT04924179 ↗

Phase 2 Unknown 25 enrolled Huazhong University of Science and Technology
NaSingle-groupOpen-labelTreatment

Summary

A Phase II Study to Assess the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and SBRT as A third-line and Posterior Line Treatment in Patients With Advanced Colorectal Cancer

Timeline

Start
2021-06-01
Primary completion
2022-12
Completion
2024-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Fruquintinib Small molecule 5 mg Oral
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous

Indications

colorectal cancer